The International Cancer of the Pancreas Screening (CAPS) Consortium recently published updated pancreatic cancer screening recommendations. The recommendations include:
- Screening with MRI/magnetic retrograde cholangiopancreaography (MRCP) and/or endoscopic ultrasound (EUS)
The screening was recommended for the following individuals:
- CDKN2A and STK11 mutation carriers starting at age 40
- BRCA1/2, ATM, PALB2, MLH1, and MSH2 mutation carriers (if they have at least one first-degree relative with pancreatic cancer) starting at age 45-50 or 10 years younger than the youngest affected relative
Check out the full article at https://www.ncbi.nlm.nih.gov/pubmed/31672839
These guidelines differ from current NCCN Pancreatic Cancer Screening Guidelines as follows:
STK11:
- CAPS: Consider screening beginning at age 40
- NCCN: Consider screening beginning at age 30-35
MSH6, EPCAM, TP53:
- CAPS: Not included
- NCCN: Consider screening beginning at age 50
CDKN2A, BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6:
- Screening recommendations remain the same as CAPS
Check out NCCN guidelines by creating a FREE account at https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf.